IN RESPONSE: I appreciate Dr. Donohoe's observations about academic medical centers that sponsor "concierge" clinics. He is correct that our paper did not specifically address academic medical centers; rather, we looked at the broader movement to practices that charge retainer fees, do not accept insurance, and/or limit the number of patients they see. ( We called such practices "direct patient contracting practices" [DPCPs] because descriptions of concierge practices commonly used in the literature lack consistency.) I agree that attention needs to be paid to the ethical, educational, and patient care implications of academic medical centers that operate such practices and on their potential effect on the poor.
However, our paper does provide a policy framework for evaluating DPCPs, which can include academic medical centers. We state, "Physicians in all types of practices must honor their professional obligation to provide nondiscriminatory care, serve all classes of patients who are in need of medical care, and seek specific opportunities to observe their professional obligation to care for the poor"; this includes physicians in academic medical centers who operate concierge clinics. We advocate that physicians consider the potential effect of changes in their practices that could make it more difficult for poorer patients to access medical care and that they consider steps to mitigate any such effect. We note that some evidence shows that concierge practices are at a greater risk for excluding poor and other vulnerable populations. However, we also note that the literature includes examples of direct primary care practices (1 variation of DPCPs) that have structured themselves to provide accessible, low-cost care to the poor, including patients enrolled in Medicaid. We conclude, "Although the growing physician interest in DPCPs may be an understandable reaction to such external factors, it must also be recognized that such models potentially exacerbate racial, ethnic, and socioeconomic disparities in health care and impose too high a cost burden on some lower-income patients."
We agree with Dr. Donohoe that little high-quality evidence is available on the clinical impact and costeffectiveness of the "extra" services often offered by DPCPs. Because good evidence on this and other effects of such practices is lacking, we propose a robust research agenda. We especially endorse the need for research on "the impact and structure of [such] models that may affect their ability to provide access to underserved populations."
Annals of Internal Medicine
I believe that it is important that, as we research and consider the policy and ethical implications of DPCPs, we also consider the external factors that are driving many physicians toward them-including excessive paperwork associated with insurance interactions, electronic health records that are designed to meet the needs of payers and regulators and not the clinical needs of physicians and their patients, and productivity-based payments that penalize physicians for spending more time with their patients. I have met many physicians who have gone into concierge and direct primary care practices precisely because they want to get back to doing what they love most, which is spending time with patients. Many say that they charge low monthly fees so that they can be accessible to moderate-and low-income patients at less out-of-pocket cost to patients than many high-deductible insurance plans offer. I caution against painting with too broad a stroke in assessing the motivations of physicians in practices that charge retainer fees or limit the numbers of patients they see and about the effect that such features have on poorer patients. Rather, we need more unbiased research and evidence-while strongly reminding physicians, as we do in our paper, of their ethical obligations to provide care that is nondiscriminatory based on a patient's income, gender and gender identity, sexual orientation, race, or ethnicity, regardless of the type of practice-concierge or not. (1) used an extended Kaplan-Meier approach to evaluate the influence of time-varying dosage (by category) on the number of days until another overdose to establish cumulative incidence curves. This approach has been shown to be flawed (2) . Kaplan-Meier estimates are suitable for time-invariant covariates only, unless strict criteria are met (conditions regarding state occupation). As noted previously, transition probabilities affect the hazards and are vital to this type of analysis (2) .
The Kaplan-Meier method that Larochelle and colleagues used in this article has been employed by many others (for example, Vigen and coworkers [3] ). To my knowledge, none of these investigators has recognized this critique.
There was an event rate of 7%, and 72% of the cohort seems to have been lost to follow-up or censored. Neither the report nor the literature suggests that this factor would be uninformative. The event and risk sets for the Kaplan-Meier calculations are due to state transitions where dosage and presence or absence in the response function vary by person. Changes in these sets are governed by such variables as censoring, participant traits, prior treatment, health status, and addiction. Because these transitions are not addressed-as they might be in, for example, a marginal structural model-we cannot derive much information from the Kaplan-Meier analysis.
Interpreting the Kaplan-Meier plot as a probability of being in the response function is more accurate (2) . How a person was included in the plot is unresolved. The results from the Cox model support the ambiguity of this aspect. The authors smartly included dosage before index overdose, sex, age, and mental health and substance abuse diagnoses in the model because they are tied to overdose events. None of these factors emerged as statistically significant in this article. However, the hazard ratios for daily dosage after the index overdose mirrored those of the Kaplan-Meier plot and reaffirmed that large intake, or "too much," is an overdose. 
Charles T. Sullivan, MS

IN RESPONSE:
We chose to use the extended Kaplan-Meier approach to provide a descriptive summary, both graphical and numerical, of the association between the category of daily opioid dosage after an opioid overdose and risk for repeated overdose. Traditional Kaplan-Meier approaches require time-invariant covariates. Snapinn and colleagues (1) summarize well the flaws of past approaches that have chosen a single time point (that is, baseline, intermediate, or end) for time-varying covariates and compare those with their suggested extended Kaplan-Meier approach that we used. Opioid prescriptions are typically dispensed monthly and may be adjusted frequently; thus, dosages may vary greatly over a long follow-up period, such as the 2 years used in our study. The extended approach allowed us to depict the cumulative incidence of repeated overdose based on the "dosage on hand" at each day in the follow-up period.
Despite these advantages, the results need to be interpreted with caution on the basis of the limitations inherent to the approach, as with any analysis. In the case of the extended Kaplan-Meier approach, Mr. Sullivan's comment and the references that he cites discuss several concerns.
First, the extended Kaplan-Meier results do not reflect fixed cohorts of participants because they are allowed to move among categories at each time point. Over time, large movements in or out of categories, along with shifts in risk level, may lead to inappropriate interpretations of the cumulative incidence curves as presented. Snapinn and colleagues recognize this limitation and suggest "pseudo percent of patients with an event" as a more appropriate term (2) .
Second, the extended Kaplan-Meier approach-like the standard Kaplan-Meier approach-is an "unadjusted" analysis that does not account for potential confounders of the relationship. As Mr. Sullivan notes, many factors may influence movement from 1 opioid dosage category to the next. We did build a complementary Cox regression model that accounts for several baseline member characteristics that reassuringly presented results similar to those of the extended KaplanMeier approach. We agree with Mr. Sullivan that the dosage transition periods (for example, from moderate to high dosage) are of interest and should be pursued in future work.
Finally, informative censoring may take place whereby there are differential reasons and rates of member dropout by opioid dosage category. As a further sensitivity analysis, we reran the Cox regression model and limited the sample to 1406 members without censoring in the first 365 days of follow-up. The effect estimates of the association between opioid dosage category and risk for repeated overdose are similar to those of the original analysis, suggesting that this type of informative censoring is less likely to have influenced our results (Table) .
In summary, we recognize that the extended KaplanMeier approach used in our article has limitations; however, when this approach is interpreted in the context of these limitations, we believe that it offers readers a useful graphical and numerical summary of the association between daily opioid dosage and risk for a repeated overdose over the follow-up period. Given these limitations, we emphasize here, as we did in our article, that the relationship presented is associative and not causal. Further work addressing these limitations is needed to move toward causality.
Follow-up to Nonfatal Opioid Overdoses
TO THE EDITOR:
Gregg's editorial (1) outlines many sensible strategies for approaching the recent plethora of opioid overdoses causing hypoventilation, hypoxia, and often death. We suggest 1 additional long-term strategy that deserves consideration: identification of phenotypes at high risk for opioidinduced respiratory depression (OIRD). Clinical observation has identified some of these-including conditions leading to chronic hypercapnia, such as severe obstructive lung disease and obesity hypoventilation syndrome (2) . Another group at high risk for OIRD includes long-term opioid users who have developed tolerance to the analgesic effects of these drugs. Animal studies and human observations have revealed that tolerance to respiratory depression develops slowly or not at all (3); thus, persons who develop tolerance to opioid analgesia and therefore tend to use increasingly higher doses are at risk, especially during sleep (4) .
Also at high risk for OIRD are those with low inherent chemosensitivity. The degree to which induced hypercapnia stimulates an increase in ventilation (hypercapnic ventilatory response) varies among the healthy population more than 80-fold. A strong argument can be made and experimental evidence suggests that a low hypercapnic ventilatory response may predict risk for OIRD (4) . Recent observations of abnormal chemosensitivity in healthy adults born at 32 weeks of gestation or less may have identified another likely high-risk population (5). The usual response to hypoxia is hyperventilation (hypoxic ventilatory response); however, some persons TO THE EDITOR: I would like to comment on Gregg's editorial (1) about prescription of opioids after an overdose (2). It is indeed ironic that, in an age of electronic health records and modern technology, simple communication of vital information is deficient. There was a time when we called one another and ensured that this information was passed on. This problem seems to require a simple solution of changing the system such that the prescribing physician is personally contacted and a formal transfer of care achieved. Gregg rightly mentions addiction as a driving risk factor in these overdoses. How do we change our best practices to adequately address cases wherein the patients who overdosed obtained medication that was not prescribed to them? Transfer of controlled substances by sale, theft, or any means is illegal in my state. When diversion is clearly documented, what are our ethical and legal obligations to inform the prescriber? What constitutes clear documentation that justifies action by a physician concerning a third-party patient from whom the medication originated?
We must address other underlying causes of accidental overdose, including such confounding medical conditions as drug interactions (especially with methadone); sepsis; dehydration; and heart, liver, lung, and renal problems (especially with morphine and oxycodone). Acute changes in health and organ function greatly affect the metabolism of some opioids, leading to drug accumulation and adverse outcomes. Some cases are due to unpredictable acute illness, and others to recurrent problems related to comorbidities. Addressing the underlying medical condition and adjusting therapy accordingly are logical and proper responses.
Finally, it seems logical to explore avenues by which partial agonists, such as transdermal buprenorphine, can be accessed as the preferred next step when long-term opioid therapy is chosen. The major barriers are financial and coverage determinations. The same obstacle exists for naloxone. Policy changes may be effective.
Pain management with opioids in patients with chronic illness can be complicated. A fragmented system of care in which the prescriber does not possess the expertise to manage the whole patient is a deficiency that must be corrected. (1) raises several questions. First, the proposed protective effect of "moderate" alcohol consumption on cardiovascular risk is stated as fact despite the authors' later acknowledgment that it is based on observational studies and subject to confounding. Indeed, a recent U.K. government review casts serious doubt on these presumed health benefits and at the same time lowers the recommended "safe" level of drinking for men from 21 to 14 units per week (2) . We believe that the medical profession must be mindful of the vast scale of alcohol-related harm when commenting about possible health benefits.
Mitchel L. Galishoff, MD
Second, the authors ignore the crucial question of why a wealthy country, such as the United States, cannot raise the bar for alcohol treatment. Instead, they note that "brief interventions can be effective for enhancing motivation" (1) without acknowledging that such low-intensity maneuvers have, at best, modest effects on surrogate end points (3). Does the National Institutes of Health promote brief interventions for hypertension or diabetes? Many nonspecialist clinicians unfortunately confuse brief intervention with motivational interviewing; the latter is highly effective but requires specific training and is lamentably not yet part of routine practice (4) . Alcohol use disorders require repeated psychosocial and medical interventions with a multidisciplinary team to deliver integrated care, as do many chronic conditions. Third, the authors rather uncritically advocate antidepressants to treat depressive symptoms in patients with unhealthy alcohol use (1) . Evidence now indicates that these agents generally have modest, if any, useful effects on mood in depressed drinkers; may paradoxically aggravate drinking outcomes; and may interact with alcohol to produce pathologic intoxication characterized by marked loss of control, memory impairment, and occasionally serious violence (including homicide) (5) .
Alcohol kills 88 000 persons annually in the United States and is the primary avoidable cause of domestic violence, microcephaly, and congenital mental impairment. Despite hitting rock bottom with these outcomes, the U.S. health system has yet to implement a comprehensive framework for alcohol control. If seen to advocate moderate alcohol consumption, the medical profession is arguably derelict in its duty to protect public health.
IN RESPONSE:
We appreciate the attention to our work and the opportunity to reply. First, we disagree with Drs. Braillon and Menkes' assertion that only experimental data should guide practice and policy-especially in areas of health that involve carcinogenic and addictive substances, where randomization poses ethical challenges. In such circumstances, methodologically rigorous observational studies can provide valid guidance (1) . Such studies show that lower-risk alcohol use is cardioprotective (2) . Regardless, because of adverse medical, psychiatric, and behavioral effects associated with alcohol and often seen in a dose-response fashion, we reiterate that "these data should not translate into recommendations for initiation of low-level alcohol use for cardioprotective effects." Second, Drs. Braillon and Menkes seem to have overlooked the important guidance we provided to clinicians on how to distinguish between at-risk drinking and an alcohol use disorder. This is a key clinical distinction, and we appreciate the opportunity to reiterate its importance in matching interventions to patients. Casual readers may accidentally conflate the 2 distinct conditions. We state specifically that brief interventions have shown efficacy in decreasing alcohol consumption only among persons with at-risk drinking (3) . We indicate that more intensive interventions, including more intensive counseling interventions and pharmacotherapy, are appropriate for those who meet criteria for alcohol use disorder (4). Such tailoring of treatment strategies to a patient's condition is consistent with recommended interventions for those with metabolic syndrome who are at risk for diabetes mellitus and hyperlipidemia. In this "at-risk" condition, counseling to promote behavioral modification may be the first line of therapy, with provision of pharmacotherapy for patients with established disease.
Finally, in a meta-analysis of 8 trials (5), use of antidepressants moderately decreased depressive symptoms in patients with depression and alcohol use disorder. We thus recommend that they be used in conjunction with counseling and addiction treatment and not in isolation. We caution against other recommendations based on case series that lack control or adjusting for confounding.
We agree with Drs. Dooley and Brown that it is important not to overlook thiamine and ascorbic acid deficiencies given their adverse consequences and treatability. As we describe, persons with unhealthy alcohol use often are malnourished and have vitamin deficiencies.
With the Patient Protection and Affordable Care Act, support is growing in the United States for creating infrastructures for screening for unhealthy alcohol use and delivering integrated and comprehensive treatment to address the range of treatment needs to improve individual and public health. 
E. Jennifer Edelman, MD, MHS
